Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

Background: The tyrosine kinase inhibitor ponatinib is the only treatment option for chronic
myelogenous leukemia patients with T315I (gatekeeper) mutation. Pharmacovigilance …

In the pasture of oncology, anticancer agents having advanced modes of action are of great
interest because of increasing chronicity of resistance against anticancer drugs. Heterocyclic …

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid
leukemia (CML) but their use was associated with a range of serious cardiopulmonary …

Chronic myeloid leukemia (CML) is a malignant disease of the hematopoietic system with
crucial pathogenic protein named BCR-ABL, which endangers the life of patients severely …

Chronic myeloid leukemia (CML) results from the reciprocal translocation between the long
arms of chromosomes 9 and 22. The translocation, t (9; 22)(q34; q11. 2) is referred to as the …

Copper-containing agents are promising antitumor pharmaceuticals due to the ability of the
metal ion to react with biomolecules. In the current study, we demonstrate that inorganic …

Despite the excellent overall survival (OS) of patients with chronic myeloid leukemia (CML),
a significant proportion will not achieve optimal response to imatinib or second-generation …

Abstract Purpose of Review This review will focus on recent and emerging treatment
paradigms in chronic phase CML. The discussion of each novel treatment or drug …